American Gene Technologies (AGT) has been given US government approval to trial a gene therapy that AGT talks of as a potential cure for HIV.The Food and Drug Administration (FDA) gave clearance for a Phase 1 trial for the research product AGT103-T starting this September in Washington and Baltimore.
AGT103-T is developed from blood cells using an 11-day process that increased T-cells, which fight HIV, but uses a lentiviral vector-based gene therapy.
Lentiviral vectors in gene therapy is a method by which genes can be inserted, modified, or deleted in organisms using lentivirus.